GHRHR
Growth hormone-releasing hormone receptor
As of the edition of 20 October 2026, GHRHR (growth hormone-releasing hormone receptor, UniProt Q02643) has 2 drugs tested at it and 2 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q02643
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 4
- Disease areas
- Nutrition and metabolism; Nervous system; Skin and connective tissue; Hormones; Immune system; Infections; Urinary and reproductive; Digestive system
- Registered trials of its drugs
- 19
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tesamorelin | Marketed | Phase 4 | Ended 2022 |
| Sermorelin acetate | Marketed | No phase stated | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Theratechnologies | Route B |
| Merck KGaA | Route B |
The other 0 companies at GHRHR
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at GHRHR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.